HBM Holdings Limited announced that, the company has completed the first dosing of first patient in two phase I trials for the treatment of advanced hepatocellular carcinoma and other solid tumors, as well as the treatment of advanced neuroendocrine neoplasm and other solid tumors in the clinical trial of HBM4003, which is the next generation anti-CTLA-4 fully human heavy-chain only antibody developed by the Company. This clinical study aims to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of HBM4003 in combination with toripalimab in patients with hepatocellular carcinoma, neuroendocrine neoplasm and other solid tumors in China. The company is developing HBM4003 as part of its product pipeline to treat multiple solid tumors with significant unmet medical needs.

Hepatocellular carcinoma and neuroendocrine neoplasm are among the first of such indications for which the Company is developing drug candidates in China.